[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644081":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":25,"responsibleParty":42,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"University Hospital, Essen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with solid malignancies",null,"performing diagnostic PET\u002FCT with a novel theranostic tracer",[13],{"name":14,"affiliation":5,"role":15},"David Kersting, MD PhD","PRINCIPAL_INVESTIGATOR",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Josephine Enste","CONTACT","+492017232073","josephine.enste@uk-essen.de",{"name":23,"role":19,"phone":20,"phoneExt":10,"email":24},"Alina Toni Küper, MD","alina.kueper@uk-essen.de",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"University Hospital Essen","RECRUITING","Essen","Germany","DE",{"type":33,"coordinates":34},"Point",[35,36],7.01228,51.45657,{"lat":36,"lon":35},[39],{"name":40,"role":19,"phone":20,"phoneExt":10,"email":41},"David Kersting, MD, PhD","david.kersting@uk-essen.de",{"type":43,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100644081","theranostic-pet-for-target-validation-and-tumor-detection-100644081",false,"NCT07664410","Theranostic PET for Target Validation and Tumor Detection","TheranosticPET","Inclusion Criteria:\n\n1. PET imaging with a theranostic PET tracer scheduled for staging or restaging of tumor types as part of clinical routine\n2. Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Patient cannot give consent for the study\n2. Patient cannot lie flat or tolerate PET imaging\n3. Unwillingness or inability to comply with study and follow-up procedures\n4. Condition of patient which is critical to participate in this study in the discretion of the investigators\n5. Pregnant, lactating, or breast-feeding women","ALL","18 Years",{"count":54,"type":55},2000,"ESTIMATED","12 Months","OBSERVATIONAL","Patients are referred for theranostic PET using different tracers as part of clinical routine for tumor staging, re-staging, and therapy planning to our department.\n\nThe aim of this study is to collect data on the expression of target molecules\u002Freceptors, proportion of PET positive tumor regions, positive predictive value, detection rate, reproducibility, and impact on clinical management of theranostic PET\u002FCT or PET\u002FMRI using novel theranostic PET tracers or other established PET tracers that are performed in theranostic concepts on patients receiving this imaging modality as part of clinical standard both at initial diagnosis and restaging before treatment decisions.\n\nPrimary Endpoint:\n\nAssociation between PET uptake intensity in theranostic PET and histopathologic expression of the respective molecular target.",[60],"Solid Malignancies","2026-06-17",{"date":63,"type":64},"2026-06-24","ACTUAL",{"date":66,"type":64},"2025-09-23",{"date":68,"type":55},"2035-09-23",{"name":5,"class":6},1]